Published in Am J Respir Crit Care Med on September 27, 2007
Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest (2012) 1.44
Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol (2010) 1.23
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum (2011) 1.22
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum (2009) 1.14
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum (2011) 1.06
Scleroderma lung disease. Eur Respir Rev (2013) 1.04
Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther (2009) 1.01
Lung involvement in systemic sclerosis. Presse Med (2010) 0.90
Imaging lung disease in systemic sclerosis. Curr Rheumatol Rep (2010) 0.88
Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol (2014) 0.83
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev (2010) 0.82
The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep (2010) 0.80
Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold? Am J Respir Crit Care Med (2008) 0.79
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.78
Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis. PLoS One (2015) 0.78
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc (2016) 0.78
Acute respiratory failure in critically ill patients with interstitial lung disease. PLoS One (2014) 0.77
Bronchoalveolar lavage and other methods to define the human respiratory tract milieu in health and disease. Lung (2011) 0.77
[Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS)]. Z Rheumatol (2008) 0.77
Challenges in the diagnosis and treatment of juvenile systemic sclerosis. Nat Rev Rheumatol (2011) 0.76
Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. Am J Respir Crit Care Med (2008) 0.75
Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters. Rheumatol Int (2010) 0.75
Histopathology and bronchoalveolar lavage. Rheumatology (Oxford) (2008) 0.75
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum (1994) 2.41
Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum (1994) 2.11
Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis (1990) 2.00
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol (2002) 1.97
Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum (1994) 1.83
BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J (2003) 1.81
Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med (2000) 1.79
Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med (1990) 1.41
Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol (1993) 1.38
Prognostic role of eosinophils in pulmonary fibrosis. Chest (1987) 1.30
Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med (1996) 1.22
Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol (2002) 1.17
Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med (1998) 1.16
Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol (2003) 1.14
Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage. Eur Respir J (1992) 1.11
The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis (2002) 1.11
Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med (1989) 1.11
Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol (1999) 1.08
Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis (2001) 1.04
Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum (2004) 1.00
Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis (2005) 0.99
A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol (1998) 0.98
Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax (1995) 0.98
Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum (1984) 0.96
Pulmonary manifestations of scleroderma. J Thorac Imaging (1992) 0.95
Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis (2001) 0.93
Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am J Respir Crit Care Med (1998) 0.93
Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis (1999) 0.92
Interstitial lung disease in systemic sclerosis. Acta Radiol (2003) 0.89
Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity. Am Rev Respir Dis (1990) 0.89
Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med (1989) 0.88
Manifestations of scleroderma pulmonary disease. Clin Chest Med (1998) 0.86
Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis. Thorax (1996) 0.83
Bronchiectasis in systemic sclerosis. A study using high resolution computed tomography. Clin Exp Rheumatol (2001) 0.82
Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. J Comput Assist Tomogr (2001) 0.82
[Latent alveolitis in systemic disease. The transition between the normal and the pathological]. Rev Mal Respir (1990) 0.81
Pulmonary function tests, high-resolution computerized tomography, alpha1-antitrypsin measurement, and early detection of pulmonary involvement in patients with systemic sclerosis. Rheumatol Int (2001) 0.81
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med (2006) 10.95
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst (2006) 6.41
A randomized study of endobronchial valves for advanced emphysema. N Engl J Med (2010) 6.23
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) (2012) 5.22
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum (2010) 4.00
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol (2008) 3.55
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Gout and the risk of acute myocardial infarction. Arthritis Rheum (2006) 2.96
Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report. J Rheumatol (2009) 2.89
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) (2012) 2.83
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80
Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis at 1 Year. J Thorac Oncol (2015) 2.75
A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest (2013) 2.71
Cardiovascular safety of tiotropium in patients with COPD. Chest (2009) 2.70
Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 2.55
The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol (2004) 2.55
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology (2009) 2.55
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 2.50
Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 2.48
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum (2008) 2.37
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2006) 2.32
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med (2013) 2.18
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.09
A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07
Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum (2010) 1.98
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest (2007) 1.92
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol (2010) 1.91
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum (2002) 1.91
Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol (2002) 1.87
Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of healthy women and women with scleroderma. Arthritis Rheum (2004) 1.85
Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med (2007) 1.85
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.84
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Observational cohort studies and well controlled clinical trials--we need them both! J Rheumatol (2004) 1.80
Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol (2009) 1.78
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
Epidemiologic review of marijuana use and cancer risk. Alcohol (2005) 1.76
Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol (2010) 1.75
Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest (2006) 1.75
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum (2011) 1.70
Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol (2008) 1.68
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab (2008) 1.67
Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol (2005) 1.67
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol (2005) 1.66
Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum (2003) 1.66
Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus. Int J Cancer (2006) 1.65
Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis. J Rheumatol (2009) 1.63
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res (2008) 1.62
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62
Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis (2012) 1.62
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum (2002) 1.61
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest (2008) 1.61
Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol (2011) 1.61
Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum (2005) 1.61
Systemic sclerosis: hypothesis-driven treatment strategies. Lancet (2006) 1.60
Diagnostic performance comparison of the Chartis System and high-resolution computerized tomography fissure analysis for planning endoscopic lung volume reduction. Respirology (2014) 1.58
Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J Rheumatol (2008) 1.58
Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol (2003) 1.57
Well controlled, double-blind, placebo-controlled trials of classical Ayurvedic treatment are possible in rheumatoid arthritis. Ann Rheum Dis (2010) 1.55
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (2012) 1.54
Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant (2013) 1.53
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53